Customize your experience
You decide what information you want to see on your Sanofi Campus
More about science
Choose a therapeutic area to find related scientific content
Diabetes
Thrombosis
Kidney Transplant
CNS
Respiratory Disease
Otolaryngeal Disorders
Latest trends
Explore the most popular scientific content among Sanofi Campus users
1st largest study of kidney transplantation in COVID-19 survivors
3 T approach for PE management
3 T approach for PE management: Dr. Janine Vintch, Dr. Prachee Sathe, Dr. Ravindra Mehta
A recent head-to head trial comparing the effectiveness of valproate versus levetiracetam
AACE Annual Meeting 2022 Coverage
AACE/ACE guidelines on insulin initiation 2020
AI Based, Personalized Epilepsy Management
Algorithms, AI, and machine learning: New horizons for predicting long-term outcomes: Presented at the ESOT 2021 congress
American Diabetes Association guidelines on insulin initiation 2021
An extensive unilateral nasal mass: Septal schwannoma - Case report
Antibody mediated rejection - Diagnosis and management: Dr. (Prof.) Dinesh Khullar
Antibody response of solid organ transplant recipients after 2-dose of SARS-CoV-2 mRNA vaccine
Support for your patients
Discover the selection of support materials for patients from different therapeutic areas
Know About Epilepsy
Myths and Facts
Steps to administer Toujeo® with TouStar® pen
Smart exercises to stay fit and safely keep diabetes in check
Pulses - A smart way to safely control blood glucose levels
Smart ways to safely enjoy the mango season
Epilepsy Do's and Don’ts
Steps to administer Lantus® with SoloStar® pen
Steps to administer Toujeo® with SoloStar® pen
Steps to administer Lantus® with AllStar® pen
Smart recipes to safely manage sweet cravings
Smart ways to safely boost the immune system
Our Products
Allegra® Suspension
Allegra® Suspension (Fexofenadine Hydrochloride Suspension) is indicated for relief of symptoms associated with allergic rhinitis in children 2-11 years of age and uncomplicated skin manifestations of chronic idiopathic urticaria in children 6 months to 11 years of age.
Allegra® Nasal
Allegra® Nasal is indicated for the treatment of symptoms of allergic rhinitis. The dosage for adults and adolescents 12 years and over is 110 mcg (two sprays in each nostril) once daily, and for children 2 to 11 years of age is 55 mcg (one spray in each nostril) once daily. Allegra® Nasal is not recommended for children under 2 years of age.
Allegra® Nasal Duo
Allegra® Nasal Duo (Fluticasone Furoate 27.5 mcg and Azelastine Hydrochloride I.P. 140 mcg) is indicated for the treatment of symptoms of allergic rhinitis. It is indicated for the management of symptoms of allergic rhinitis, once the need for an antihistamine and corticosteroid has been established. It is recommended for the treatment of persistent, moderate to severe symptoms in adults and adolescents above 12 years of age.
Amaryl® M
Amaryl® M is fixed dose combination tablets of Metformin Hydrochloride Prolonged Release & Glimepiride. Amaryl® M is indicated for the management of patients with type 2 diabetes mellitus when diet, exercise and single agent (Glimepiride or Metformin alone) do not result in adequate glycemic control.
Amaryl® MP
Amaryl® MP is fixed dose combination tablets of Metformin Hydrochloride Sustained Release, Glimepiride & Pioglitazone Hydrochloride. Amaryl® MP is indicated as third line treatment of Type II diabetes mellitus in adult patients when diet, exercise and the single agents and second line therapy with two drugs do not result in adequate glycemic control.
Amaryl® MV
Amaryl® MV is fixed dose combination tablets of Metformin Hydrochloride (SR), Glimepiride & Voglibose. Amaryl® MV is indicated as third line treatment of Type II diabetes mellitus in adult patients when diet, exercise and the single agents and second line therapy with two drugs do not result in adequate glycemic control.
Amaryl® and Semi-Amaryl®
Semi-Amaryl® / Amaryl® is Glimepiride tablets which is an oral antidiabetic agent of the sulphonylurea group. Glimepiride is indicated for non-insulin dependent (type II) diabetes mellitus, whenever blood glucose levels cannot be controlled adequately by diet, physical exercise and weight reduction alone. Glimepiride may be combined with other, non-betacytotropic, oral antidiabetics. Glimepiride may also be used together with insulin (see dosage and administration).
Cardace®
Cardace® is Ramipril Tablets IP. Cardace® is indicated for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmHg or diastolic blood pressure > 90mmHg (or on antihypertensive treatment); total cholesterol >5.2mmol/L; HDL cholesterol < 0.9mmol/L; current smoker; known microalbuminuria; any evidence of previous vascular disease. Prevention of myocardial infarction, stroke or cardio-vascular death and reduction of need for revascularization procedures in patients with an increased cardiovascular risk such as manifest coronary heart disease, a history of stroke or a history of peripheral vascular disease. Treatment of patients who within the first few days after an acute myocardial infarction have demonstrated clinical signs of congestive heart failure. Treatment of hypertension and cardiac failure. Treatment of non-diabetic or diabetic overt glomerular or incipient nephropathy.
Cardace® H
Cardace® H is fixed dose combination of Ramipril & Hydrochlorothiazide Tablets IP. Cardace® H is indicated for the treatment of mild to moderate hypertension in patients (in whom combination therapy is appropriate) who have been stabilized on the individual components given in the same proportion.
Cardace® Protect
Cardace® Protect is fixed dose combination of Ramipril & Atorvastatin Tablets. Cardace® Protect is indicated for treatment of patients with both essential hypertension and hypercholesterolemia. Ramipril has been found to reduce risk of MI, stroke or cardiovascular death in patients with increased risk. Atorvastatin has been found to reduce the risk of MI, stroke, revascularization procedures and angina in patients with CHD.
Synvisc-One™
Hylan® G-F 20 (Synvisc-One™) is indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non pharmacologic therapy and to simple analgesics and for the treatment to decrease pain and discomfort allowing more extensive movement of the knee.
Valparin®
VALPARIN® (Valproate + Valproic Acid) is indicated for the treatment of generalized or partial epilepsy particularly with the following patterns of seizures: absence, myoclonic, tonic-clonic, atonic, mixed, as well as for partial epilepsy and manic episodes associated with bipolar disorder.
Vinlep™
VINLEP™ (oxcarbazepine) is indicated as Monotherapy and adjunctive therapy in the treatment of partial seizures (which include seizure subtypes of simple, complex and partial seizures evolving to secondarily generalized seizures) in adult patients. Treatment of generalized tonic-clonic seizures in adults and children. Adjunctive therapy in the treatment of partial seizures in children aged 4 -16 years. Monotherapy in the treatment of partial seizures in children aged 4-16 years.
Vinlep™ Suspension
Vinlep™ Suspension (Oxcarbazepine) is indicated in adults and children aged 1 month and above for the treatment of :
- Partial seizures (which include the seizure subtypes of simple, complex and partial seizures evolving to secondarily generalized seizures)
- Generalized tonic-clonic seizures
Disclaimer: The images depicted here are fictitious and meant for illustrative purpose only. Any resemblance to any person, living or dead is purely coincidental.
This website is intended exclusively for Registered Medical Practitioners in India.
Please select the tab below to continue.